---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-006188"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2025-09-30T23:59:59+00:00"
generated_at: "2026-05-17T05:15:33.731383+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech amends CAD$23M gov't agreement, extends timeline to Dec 2028, shifts EB05 focus to general ARDS

## Summary
- Project completion extended to December 31, 2028 (from December 31, 2025); agreement expiration extended to later of Dec 2045 or last repayment.
- First annual repayment due in 2032 (from 2029) and only if the Company earns gross revenue.
- Clinical focus for EB05 changed to general ARDS from COVID-19 induced ARDS; company gains access to fully funded US government platform study.
- Amendment adds reporting requirements on similar EB05 development projects and updates milestones/timelines.
- Government of Canada committed up to CAD$23M ($17M USD) in partially repayable funding under original agreement.

## SEC filing metadata
- accession: 0001171843-25-006188
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2025-09-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184325006188/0001171843-25-006188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184325006188/f8k_093025.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-006188
- JSON: https://secwatch.observer/filing/0001171843-25-006188.json
- Plain text: https://secwatch.observer/filing/0001171843-25-006188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.